Market revenue in 2020 | USD 1,430.2 million |
Market revenue in 2028 | USD 2,841.4 million |
Growth rate | 9% (CAGR from 2020 to 2028) |
Largest segment | Laboratory technologies |
Fastest growing segment | Online Technologies |
Historical data | 2020 - 2019 |
Base year | 2020 |
Forecast period | 2021 - 2028 |
Quantitative units | Revenue in USD million |
Market segmentation | Laboratory Technologies, Online Technologies |
Key market players worldwide | Thermo Fisher Scientific Inc, Pfizer Inc, Sartorius AG, Stemcell Holdings Inc Ordinary Shares, Illumina Inc, Agilent Technologies Inc, Bio-Rad Laboratories Inc, Danaher Corp, Merck KGaA, Qiagen NV, Shimadzu Corp, Eurofins Scientific SE, Charles River Laboratories International Inc, Takara Bio Inc, Olympus Corp, Avantor Inc, Aurora Innovation Inc Class A, Standard BioTools Inc, Celerion, Cole-Parmer, Hartford Schroders International Stk I, Revvity Inc, Fluidigm Corporation, Polyplus-transfection, Hamilton Lane Inc Class A |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to covid-19 vaccine development tools market will help companies and investors design strategic landscapes.
Laboratory technologies was the largest segment with a revenue share of 95.51% in 2020. Horizon Databook has segmented the India covid-19 vaccine development tools market based on laboratory technologies, online technologies covering the revenue growth of each sub-segment from 2020 to 2028.
The COVID-19 pandemic significantly boosted growth of Indian pharmaceutical and biotech companies. The growth rate that was estimated in pre-Covid scenario in 5-6 years was covered within 2 years during the pandemic. The competitive advantage for India was that it could develop COVID-19 vaccine and manufacture it on a large scale.
The country can manufacture over 2.4 billion doses yearly and had sufficient medical & surgical disposables. The manpower and established cold-chain infrastructure before the pandemic were adequate to vaccinate at least 30 million people.
Various local companies collaborated with foreign-based vaccine developers to conduct clinical trials and produce & distribute vaccines on a large-scale. For instance, the Serum Institute of India (SII) agreed with manufacturers, including Codagenix, Oxford-AstraZeneca, and Novavax, to produce the vaccine at a large scale.
Horizon Databook provides a detailed overview of country-level data and insights on the India covid-19 vaccine development tools market , including forecasts for subscribers. This country databook contains high-level insights into India covid-19 vaccine development tools market from 2020 to 2028, including revenue numbers, major trends, and company profiles.
No related regions found.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account